Zolpimist is in the market of potential 2bn market size while Artimist has a potential of only 500m market size. i would bank on the existing Zolpimist product producing huge revenues and once people realise SUD already has products on sale with future new products soon to be online, the SP will sky rocket. SUD is not just a biotech doing clinical trials, it already is selling Zolpmist product with many rave reviews from patients ! With Zolpimist being a success in a 2bn market size, hopefully we will see dividends from SUD !
SUD, page-11
-
- There are more pages in this discussion • 4 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
